TargetBeta
CD47
CD47 molecule · also IAP, OA3, MER6 · CD molecules
5 programs in company-led studies act on CD47, from 5 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ligufalimabrule | Akeso | phase 3 | 118 running | – | NCIt |
| evorpaceptrule | ALX Oncology | phase 3 | 93 running | – | ChEMBL |
| Anti-PD-1/CD47 Fusion Protein HX009rule | Hangzhou Hanx Biopharmaceuticals | phase 2 | 52 running | PDCD1 | NCIt |
| CD47 Antagonist AUR103 Calciumrule | Dr. Reddy's Laboratories | phase 2 | 21 running | – | NCIt |
| 1200mg of tqb2928 injection | Sino Biopharmaceutical | phase 1 | 21 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Neoplasms, 2 programs
- Stomach Neoplasms, 2 programs
- Biliary Tract Neoplasms, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Lymphoma, 1 program
- Myelodysplastic Syndromes, 1 program
- Neoplasm Metastasis, 1 program
- Osteosarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026ligufalimab · Akeso · phase 3 · NCT05227664
- Dec 2027evorpacept · ALX Oncology · phase 3 · NCT07007559
- Dec 31, 2027Anti-PD-1/CD47 Fusion Protein HX009 · Hangzhou Hanx Biopharmaceuticals · phase 2 · NCT06708663
- Dec 30, 2028CD47 Antagonist AUR103 Calcium · Dr. Reddy's Laboratories · phase 2 · NCT07640737
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.